Update - Proposed issue of securities - RAD
Released
Released
Announcement PDF
Appendix 3B - Proposed issue of securities
Update Summary
Entity name
RADIOPHARM THERANOSTICS LIMITED
Announcement Type
Update to previous announcement
Date of this announcement
6/2/2024
Reason for update to a previous announcement
Issue of shares varied per addendum released 6 February 2024
- 8,800,000 Shares are being issued pursuant to LR 7.1
- 20,000,000 Shares are being issued pursuant to LR 7.1A
Refer to next page for full details of the announcement
Appendix 3B - Proposed issue of securities
1/5
Appendix 3B - Proposed issue of securities
Part 1 - Entity and announcement details
1.1 Name of +Entity
RADIOPHARM THERANOSTICS LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees
to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in
Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also
apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set
out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under
the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX
an Appendix 2A online form notifying ASX of their issue and applying for their quotation).
1.2 Registered Number Type
Registration Number
ACN
647877889
1.3 ASX issuer code
RAD
1.4 The announcement is
Update/amendment to previous announcement
1.4a Reason for update to a previous announcement
Issue of shares varied per addendum released 6 February 2024
- 8,800,000 Shares are being issued pursuant to LR 7.1
- 20,000,000 Shares are being issued pursuant to LR 7.1A
1.4b Date of previous announcement to this update
6/2/2024
1.5 Date of this announcement
6/2/2024
1.6 The Proposed issue is:
A placement or other type of issue
Appendix 3B - Proposed issue of securities
2/5
Appendix 3B - Proposed issue of securities
Part 7 - Details of proposed placement or other issue
Part 7A - Conditions
7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other
type of issue can proceed on an unconditional basis?
No
Part 7B - Issue details
Is the proposed security a 'New
class' (+securities in a class that is
not yet quoted or recorded by ASX)
or an 'Existing class' (additional
securities in a class that is already
quoted or recorded by ASX)?
Existing class
Will the proposed issue of this
+security include an offer of
attaching +securities?
No
Details of +securities proposed to be issued
ASX +security code and description
RAD : ORDINARY FULLY PAID
Number of +securities proposed to be issued
28,800,000
Offer price details
Are the +securities proposed to be issued being issued for a cash
consideration?
No
Please describe the consideration being provided for the +securities
Per Share Subscription Agreement announced 6 February 2024, the Company will issue shares which may subsequently
be applied towards satisfying the Company's issue of Subscription Shares or repayment obligations under the Agreement
Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities
0.059000
Will these +securities rank equally in all respects from their issue date with
the existing issued +securities in that class?
Yes
Appendix 3B - Proposed issue of securities
3/5
Appendix 3B - Proposed issue of securities
Part 7C - Timetable
7C.1 Proposed +issue date
13/2/2024
Part 7D - Listing Rule requirements
7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
No
7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15%
placement capacity under listing rule 7.1?
Yes
7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity's 15%
placement capacity under listing rule 7.1?
8,800,000
7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's
additional 10% placement capacity under listing rule 7.1A (if applicable)?
Yes
7D.1c ( i ) How many +securities are proposed to be issued without +security holder approval using the entity's
additional 10% placement capacity under listing rule 7.1A?
20,000,000
7D.1c ( ii ) Please explain why the entity has chosen to do a placement rather than a +pro rata issue or an offer
under a +security purchase plan in which existing ordinary +security holders would have been eligible to
participate
The Placement complements the recent Entitlement Offer.
7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?
No
7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?
No
7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?
No
Part 7E - Fees and expenses
7E.1 Will there be a lead manager or broker to the proposed issue?
No
7E.2 Is the proposed issue to be underwritten?
No
7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue
Full details are set out in the announcement dated 6 February 2024 'RAD secures Share Facility Agreement of up to
A$12.5m'
Appendix 3B - Proposed issue of securities
4/5
Appendix 3B - Proposed issue of securities
Part 7F - Further Information
7F.01 The purpose(s) for which the entity is issuing the securities
Funds raised will support the clinical trial pipeline and otherwise for general working capital of the Company.
7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?
No
7F.2 Any other information the entity wishes to provide about the proposed issue
Full details are set out in the announcement and addendum dated 6 February 2024 'RAD secures Share Facility
Agreement of up to A$12.5m'
7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with
the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)
Appendix 3B - Proposed issue of securities
5/5
Share your feedback
Discover